1. Scrip
  2. >>Business
  3. >>Strategy

Pressed Sanofi CEO Hopes For Positive Dupixent Launch, Praluent Ruling

 
• By Sten Stovall

Sanofi's CEO Olivier Brandicourt's reassuring 2017 guidance relies on continued cost savings, a successful launch of its Dupixent biologic, and winning a US legal case that threatens its PCSK9 inhibitor Praluent.

Sanofi reported slightly better than expected fourth-quarter results and reassuring guidance for 2017 on Feb. 8 - but analysts said real growth remains elusive for the French drugmaker and that its immediate prospects largely hinge on launching its Dupixent (duplimumab) therapy for atopic dermatitis and also winning a pending patent infringement case that threatens sales of its PCSK9 inhibitor Praluent (alirocumab).

The Paris-based group – which Olivier Brandicourt has revamped since taking over as CEO in April 2015 – also faces...

More from Strategy

More from Business

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.